Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma
Journal of Clinical Investigation · 06.10.2026
DOI: 10.1172/jci204613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 06.10.2026. Verfasst von Katrine N Madsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, United States of America. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense/War Congressionally Directed Medical Research Program, Yale School of Medicine, NIH/NCI.
Abstract (Originalsprache)
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhibition could impair antitumor immunity. However, whether pharmacologic HIF-2α inhibition alters human T cell biology remains unknown. Here, we investigated the cell-intrinsic effects of EPAS1 (encoding HIF-2α) perturbation in primary human T cells. CRISPR/Cas9-mediated deletion of HIF-2α demonstrated no notable transcriptional effects. Similarly, pharmacologic treatment with belzutifan produced minimal transcriptional changes and did not impair proliferation, cytokine production, polyfunctionality, or cytotoxic activity in T cells derived from healthy donor peripheral blood, peripheral blood from patients with ccRCC, or tumor-infiltrating lymphocytes under hypoxic conditions. High- dimensional immunophenotyping revealed preserved T cell differentiation and activation states following pharmacologic HIF-2α inhibition in vitro and in peripheral blood from patients receiving HIF-2α inhibitor therapy. Together, these findings demonstrate that pharmacologic HIF-2α inhibition preserves key effector programs, providing a mechanistic basis for the immunologic safety of HIF-2α–targeted therapy in ccRCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, United States of America.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America.
- Department of Urology, Yale School of Medicine, New Haven, United States of America.
- Department of Pathology, Yale School of Medicine, New Haven, United States of America.
- Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, United States of America.
Förderung
- Department of Defense/War Congressionally Directed Medical Research Program
- Yale School of Medicine
- NIH/NCI
- DF/HCC Kidney Cancer SPORE
- Yale Cancer Center
Zitieren
APA
Madsen, K. N., Kashima, S., Soulati, H., Wirth, L., Ito, K., Yochum, Z. A., Moritz, V., Walker, J., Machaalani, M., Ghali, F., Kenney, P., Adeniran, A., Hurwitz, M., Choueiri, T. K., & Braun, D. A. (2026). Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci204613
Vancouver
Madsen KN, Kashima S, Soulati H, Wirth L, Ito K, Yochum ZA, et al. Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma. Journal of Clinical Investigation. 2026. doi:10.1172/jci204613
BibTeX
@article{Madsen2026,
author = {Madsen, Katrine N and Kashima, Soki and Soulati, Hanna and Wirth, Lena and Ito, Katsuhiro and Yochum, Zachary A and Moritz, Vivien and Walker, Julia and Machaalani, Marc and Ghali, Fady and Kenney, Patrick and Adeniran, Adebowale and Hurwitz, Michael and Choueiri, Toni K and Braun, David A},
title = {Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci204613}
}
EUVIMED